After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization